Key Points
- COO Chuck Ence purchased 136,000 shares on November 5 at $2.20 each (~$299,200), bringing his total to 403,931 shares — a 50.76% increase in his ownership per the SEC filing.
- Shares traded up about 4% recently; the company has a market cap of ~$86.6M, negative EPS, a 12‑month range of $0.24–$3.43, and an analyst consensus of "Reduce" with a $1.00 target.
Relmada Therapeutics, Inc. (NASDAQ:RLMD - Get Free Report) COO Paul Edward Kelly acquired 90,000 shares of the firm's stock in a transaction that occurred on Wednesday, November 5th. The stock was bought at an average price of $2.20 per share, with a total value of $198,000.00. Following the completion of the acquisition, the chief operating officer directly owned 502,295 shares of the company's stock, valued at $1,105,049. This trade represents a 21.83% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Relmada Therapeutics Price Performance
Shares of NASDAQ:RLMD opened at $2.61 on Friday. Relmada Therapeutics, Inc. has a 1 year low of $0.24 and a 1 year high of $3.43. The business's 50-day moving average is $1.94 and its 200-day moving average is $1.06. The company has a market capitalization of $86.63 million, a price-to-earnings ratio of -1.18 and a beta of 0.87.
Relmada Therapeutics (NASDAQ:RLMD - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported ($0.30) EPS for the quarter, missing analysts' consensus estimates of ($0.25) by ($0.05). Analysts anticipate that Relmada Therapeutics, Inc. will post -2.73 EPS for the current year.
Analyst Upgrades and Downgrades
A number of equities research analysts have issued reports on the stock. Wall Street Zen raised shares of Relmada Therapeutics to a "hold" rating in a research report on Saturday, October 11th. Weiss Ratings reiterated a "sell (e+)" rating on shares of Relmada Therapeutics in a report on Friday, October 31st. Three investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Reduce" and a consensus price target of $1.00.
Get Our Latest Stock Report on RLMD
Institutional Investors Weigh In On Relmada Therapeutics
Institutional investors and hedge funds have recently made changes to their positions in the business. XTX Topco Ltd bought a new stake in Relmada Therapeutics during the second quarter valued at $28,000. Goldman Sachs Group Inc. purchased a new stake in shares of Relmada Therapeutics in the 1st quarter valued at about $33,000. LMR Partners LLP bought a new stake in shares of Relmada Therapeutics during the 2nd quarter valued at about $33,000. Jane Street Group LLC purchased a new position in shares of Relmada Therapeutics during the second quarter worth about $69,000. Finally, Marshall Wace LLP bought a new position in shares of Relmada Therapeutics in the second quarter worth approximately $93,000. Hedge funds and other institutional investors own 45.24% of the company's stock.
About Relmada Therapeutics
(
Get Free Report)
Relmada Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
